Mycobacterium avium-M. intracellulare is a frequent cause of late disseminated infection in patients with AIDS. The ability of human peripheral blood monocytes to phagocytose and kill M. avium was examined in an in vitro model. Monocytes were obtained from 13 healthy volunteers and 11 patients with AIDS, three of whom had documented disseminated M. avium infection. Monocytes were precultured for 2 days before infection with two AIDS-associated and two non-AIDS-associated strains of M. avium. Uptake of M. avium as measured by counting intracellular acid-fast bacilli did not differ among healthy subjects, patients with AIDS, or patients with AIDS and previously documented disseminated M. avium infection. Intracellular growth of M. avium was examined by a CFU assay of cel lysates from M. avium-infected monocytes after 0, 4, and 7 days of culture. Intracellular growth inhibition of M. avium at 7 days after infection was comparable between patients with AIDS and healthy donors for all M. avium strains tested. The effects of the addition of recombinant gamma interferon on M. avium uptake and intracellular growth in monocytes also were studied. Pretreatment of monocytes with gamma interferon prior to infection suppressed monocyte phagocytosis of M. avium. Continuously coculturing of monocytes with gamma interferon after infection augmented killing of M. avium among both patients with AIDS and healthy controls for three of the four strains of M. avium tested. The magnitude of this effect, however, was variable from donor to donor and strain to strain. No significant differences were noted between the growth-inhibiting abilities of gamma-interferon-treated monocytes obtained from healthy volunteers and those obtained from patients with AIDS.
Disseminated Mycobacterium avium-M. intracellulare infection is a common late opportunistic infection in patients with AIDS (12, 13, 17) . Disseminated M. avium infection occurs as the initial AIDS-defining condition in 3 to 4% of AIDS cases (3) , and evidence of disseminated M. avium infection has been present at the time of death in up to 47 to 56% of autopsied patients with AIDS (9, 42) . This finding is in striking contrast to the rarity of clinically significant infection with this ubiquitous organism in immunocompetent hosts. In addition to increased numbers of disseminated M. avium infections in such patients, patients with AIDS also have an increased incidence of infection with other nontuberculous mycobacteria and tuberculosis (38) .
Mononuclear phagocytic cells are key effector cells in the immune response to intracellular pathogens such as mycobacteria. Monocytes can be infected in vitro with human immunodeficiency virus (HIV) (14, 24) , and blood monocytes and tissue macrophages are infected in vivo (15, 27, 32) . Since only 1 to 5% of normal blood-derived monocytes/ macrophages were directly infectible with HIV in vitro (14) and the level of viral replication appears to be lower in monocytes/macrophages than in lymphocytes, alterations in monocyte functional ability in patients with AIDS are likely to be indirectly mediated. Previous studies have documented normal effector functions of monocytes isolated from patients with AIDS, including oxidative burst generation and intracellular killing or inhibition of Toxoplasma gondii or Chlamydia psittaci (19) , killing of aspergilli and cryptococci (43) , phagocytosis of latex particles, expression of interleukin 1, and antibody-dependent cellular cytotoxicity against WEHI 164 sarcoma cells (26) ; defective monocyte accessory * Corresponding author.
cell function for lymphocyte responses to soluble antigens (29) and mitogens (28) has, however, been reported recently. Selective impairment of macrophage chemotaxis to several chemoattractants, including lymphocyte-derived chemotactic factor and N-formyl-methionyl-teucyl-phenylalanine, in patients with AIDS also has been reported (26, 37) . Conflicting data exist regarding monocyte effector function capability against mycobacteria in patients with AIDS; both normal (34) and decreased (4) abilities to limit intracellular M. avium growth have been described.
Gamma interferon (IFN-y), which is a product of stimulated T cells, increases intracellular killing of T. gondii (18, 21, 23) , Leishmania species (7, 25) and other pathogens (2, 8, 31) . Whereas the addition of IFN--y to murine macrophages enhances mycobacterial killing (10, 11) , the effects of IFN--y on mycobacterial killing by human monocytes are controversial. Investigators have shown that IFN--y has variable effects on the intracellular growth of Mycobacterium tuberculosis in human monocytes and macrophages (7, 30, 40 avium infection fail to undergo blastogenesis when exposed to bacillus Calmette-Guerin (M. bovis BCG)-or M. aviumderived antigens and that such patients' lymphocytes secrete only very low levels of IFN-y in response to these antigens (21) . Monocytes and tissue macrophages from patients with AIDS are, however, fully responsive to the effects of IFN--y in vitro; stimulation with this cytokine leads to augmented release of hydrogen peroxide after exposure to phorbol myristyl acetate, and increased killing of T. gondii (predom-inantly oxygen-dependent killing) and growth inhibition of C. psittaci (predominantly oxygen-independent killing) (18, 19) .
The purpose of this study was to examine the effector function of 2-day-precultured monocytes, a population of cells relatively nonpermissive to the growth of intracellular pathogens, from healthy subjects, patients with AIDS, and patients with AIDS and known concurrent disseminated M. avium infection in an in vitro model of M. avium infection. We found comparable abilities of monocytes from healthy subjects and patients with AIDS to ingest and limit the intracellular growth of several AIDS-and non-AIDS-associated strains of M. avium and to respond to IFN--y.
MATERIALS AND METHODS
Human subjects. Eleven patients with AIDS (10 males and 1 female; 24 to 38 years old; mean age, 31 + 5 years) were studied. Three patients with AIDS had known disseminated M. avium infection as documented by repeated positive blood cultures prior to the time of study. None of the patients was receiving antimycobacterial drug therapy at the time of study. Seven of the patients had previous Pneumocystis carinii pneumonia (four within 4 weeks prior to study).
Three of the patients were completing acute treatment for Pneumocystis pneumonia with trimethoprim-sulfamethoxazole or trimethoprim-dapsone at the time of study. Two patients were receiving trimethoprim-sulfamethoxazole or trimethoprim-dapsone as secondary prophylaxis against recurrent Pneumocystis pneumonia. All patients with AIDS except one (who had AIDS-related encephalopathy as the AIDS-defining condition) had previously documented opportunistic infections usually with P. carinii or esophageal candidiasis. Three patients were receiving daily treatment with zidovudine. The clinical spectrum of the patients with AIDS studied ranged from recently diagnosed cases presenting with an initial opportunistic infection to late advanced disease. The time since the diagnosis of AIDS was established was 6.7 ± 7.7 months (mean + standard deviation, with a range of 1 to 24 months). The group of healthy volunteers included 13 subjects (7 males and 6 females, 24 to 43 years old; mean age, 31 years) who were not in any group recognized to be at increased risk for HIV infection.
Microorganisms. Four M. avium strains were used in these experiments. Strains 86m2096 and LR542 were clinical isolates from patients with AIDS and disseminated M. avium infection. M. avium LR542 and LR114 (parent strain) were kindly donated by J. F. Crawford, John L. McClellan Memorial Veterans Hospital, Little Rock, Ark., and were serovar 4. Strain 86m2096 was a clinical isolate from University Hospital, Cleveland, Ohio. Strains LR114F and LR114R have flat, transparent and round, opaque colonial morphologies and were separated on this basis from a non-AIDS isolate. Strains LR114F and 86m2096 were highly virulent strains as defined by rapid intracellular growth and short dividing times in previous experiments, whereas strains LR542 and LR114R were of low virulence or relatively avirulent (36, 41) . Strains of M. avium were grown in Middlebrook 7H9 broth supplemented with ADC enrichment (Difco Laboratories, Detroit, Mich.) at 37°C and 5.0% CO in air. When the bacterial density was approximately 1 x 10i to 5 x 108/ml (log-phase growth), the mycobacteria were aliquoted into freezing tubes (Nunc, Copenhagen, Denmark) and stored at -70°C until use. Before infection, bacteria were thawed in a 37°C water bath and sonicated for 5 The numbers of monocytes in representative plates were determined before the 2-day preculture period, immediately after infection (day 0), and at 4 and 7 days after infection by the method of Nakagawara and Nathan (22) . The CFU assay. The CFU assay was performed as described previously (35, 36, 41 this study. Uptake of M. avium was assayed by direct-light microscopic enumeration of cell-associated M. avium after Kinyoun staining. Pretreatment of monocytes derived from patients with AIDS with IFN--y (300 U/ml) significantly decreased the percentage of monocytes infected with M. avium for all four strains of M. avium tested and decreased the number of AFB ingested per 100 infected monocytes for the two more virulent M. avium strains (P < 0.05, paired t test) ( Table 1) . Modulation by IFN--y of the intracellular growth of M. avium by peripheral blood monocytes from patients with AIDS. Monocytes from patients with AIDS and healthy subjects were precultured for 2 days and infected with four strains of M. avium. The infected monocytes were then cultured continuously in the presence (10 to 1,000 U/ml) or absence of human recombinant IFN--y for up to 7 days. Representative plates were harvested immediately after infection (day 0) and at 4 and 7 days. Intracellular growth of M. avium was measured as the CFU count of M. avium in monocyte cell lysates at each respective time point after infection. Dose-response experiments showed that the optimal dose of IFN-y causing intracellular M. avium growth inhibition was 300 U/ml for both patients with AIDS and healthy subjects. At suboptimal doses, IFN--y augmented intracellular M. avium growth inhibition in a comparable and dose-dependent fashion for both patients with AIDS and healthy subjects (data not shown). No further increase in intracellular M. avium growth inhibition was seen when monocytes from patients with AIDS were cultured with higher doses of IFN--y (1,000 U/ml) ( Table 2) .
Culturing infected monocytes continuously in the presence of IFN--y (300 U/ml) decreased intracellular growth of M. avium at 4 or 7 days by 30 to 50% for patients with AIDS (P < 0.05 for three of four strains of M. avium tested, paired t test) (Fig. 2) . Studies using monocytes from healthy donors were performed concurrently with the studies using monocytes from patients with AIDS. There were no significant differences between the effects of IFN--y on intracellular M. avium growth in monocytes derived from patients with AIDS and in monocytes derived from healthy subjects (36) . IFN--y had no direct effect on M. avium growth in culture medium without monocytes (35) .
DISCUSSION
This study shows that monocytes obtained from the peripheral blood of patients with AIDS have preserved effector cell function with regard to their ability to phagocytose and limit the intracellular growth of M. avium compared with monocytes derived from healthy donors. These data confirm the earlier data obtained by Schnittman et al. that monocytes from patients with AIDS exhibit capacities for M. avium uptake and killing comparable to those of monocytes from healthy individuals (34) (1) . Some of the variability in the results is likely due to differences in the source and duration of preculture of mononuclear phagocytes, differences in virulence among M. avium strains, and interspecies differences in susceptibility to mycobacterial infection (33, 36) .
Our data demonstrate that monocytes derived from patients with AIDS can be stimulated by a known macrophageactivating factor such as IFN-y to augment the capability to limit intracellular growth of M. avium. These results were obtained by using doses of IFN--y demonstrated to have optimal macrophage-activating factor activity in experiments with monocytes from patients with AIDS and healthy subjects (36) . The absolute decrease in colony counts in the presence of IFN-y was small but similar to that of monocytes from healthy subjects. In earlier experiments, Schnittman et al. demonstrated IFN-y enhancement of intracellular M. avium growth inhibition by monocytes from healthy subjects but not patients with AIDS. Lower doses of IFN--y (200 U/ml) were used in those studies. In dose-response studies, however, we observed comparable levels of intracellular M. avium growth inhibition in monocytes from patients with AIDS and healthy subjects at doses of IFN--y ranging from 10 to 300 U/ml. Other cytokines, including interleukins 2, 3, 4, and 6 and macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, failed to augment intracellular M. avium growth inhibition in monocytes from healthy donors (35 (19) and when stimulated by heat-killed BCG or soluble M. intracellulare antigens (20) . The surface expression of receptors for IFN--y on peripheral blood mononuclear cells from patients with AIDS and AIDS-related complex was normal (16) . When stimulated in vitro by exogenous IFN--y, monocytes from patients with AIDS showed increased oxidative-burst activity and antimicrobial activity against T. gondii and C. psittaci comparable to those of IFN--y-stimulated monocytes from healthy subjects (19) . Our data extend these observations by demonstrating that continuous culture of monocytes from patients with AIDS in the presence of IFN--y results in augmentation of the ability of these cells to inhibit intracellular M. avium growth. Whereas the observed in vitro effects of IFN-y are small, the culture condition may introduce a bias in favor of the bacteria, and options for treatment of disseminated M. avium infections remain extremely limited. Limited clinical trials of recombinant human IFN--y in combination with antimycobacterial drug therapy in patients with AIDS and disseminated M. avium infection are ongoing (39) . Given the complexity of the host-microbial interactions in M. avium infection and our present inability to reconstitute or restore CD4+ lymphocyte function in patients with AIDS, multiple modality therapy with both immunomodulating substances and antimycobacterial drug therapy, therefore, may offer a reasonable therapeutic option.
